By Doug Macron

Alnylam Pharmaceuticals last week disclosed that long-time partner Novartis has decided not to acquire broad, non-exclusive access to the RNAi drug shop's intellectual property and technologies — a transaction that would have been worth $100 million to Alnylam.

Concurrent with the announcement, Alnylam said that it was cutting between 25 percent and 30 percent of its workforce, which is expected to cost up to $3 million in one-time charges this year but save the company $25 million in 2011.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.